Policy Watch
Payer changes that affect infusion
Short write-ups of payer policy changes for clinic-administered biologics: what moved, who it applies to, and when it takes effect. Each one links to the payer's own document.
Effective Jan 1, 2027
Aetna Commercial's January changes: bevacizumab, trastuzumab, checkpoint inhibitors and more
Eight classes move, and four products change status for one site of care only.
Effective Nov 1, 2026
Anthem Commercial names its first preferred denosumab biosimilars
Two biosimilars join Prolia and two join Xgeva. Anthem's Medicare tables still prefer the reference products alone.
Revised Sep 2, 2026
Humana Medicare Advantage swaps its preferred trastuzumab
Kanjinti and Ogivri traded places. Some patients already on Kanjinti are exempt from the new step.